Healthcare • Biotechnology
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ABVX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
98 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
302 filers reported a long position in ABVX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| TCG Crossover Management, LLC | $800.6M | 6M | -7.3% |
| Helikon Investments Ltd | $371.4M | 2.8M | +175% |
| Darwin Global Management, Ltd. | $348.2M | 3.6M | +4.4% |
| Vestal Point Capital, LP | $313.1M | 2.3M | +56.6% |
| Jupiter Topco LLC | $255.1M | 1.9M | — |
| UBS Group AG | $245.9M | 1.8M | -59.4% |
| ADAR1 Capital Management, LLC | $240.5M | 1.8M | +29.5% |
| Caligan Partners LP | $207.6M | 1.6M | +6.6% |
| CITADEL ADVISORS LLC | $191.7M | 1.4M | +164.2% |
| MORGAN STANLEY | $190.9M | 1.4M | -16% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.